Presentation (CTI)

OBJECTIVES: Respiratory syncytial virus (RSV) infection is a major cause of lower respiratory tract illness (LRTI) in older adults. Following the approval of the novel RSVpreF vaccine in Mexico for adults aged 60 years and older, this study evaluated the clinical and economic impact of RSV-LRTI among older adults, with and without a year-round RSVpreF vaccination program.
METHODS: A Markov model simulated RSV-related clinical and economic outcomes in older adults with and without RSVpreF vaccination. Input parameters were derived from published sources; vaccine efficacy was based on data from the “RENOIR” clinical trial; vaccine uptake rate (57.7%) was assumed to be equivalent to influenza vaccination rates in Mexico. Analyses adopted a healthcare system perspective, incorporating direct costs (2025 MXN[US$]) and discounting future costs and outcomes at 5% annually. Scenario and sensitivity analyses were conducted to assess model robustness.
RESULTS: Among adults 60 years and older, the projected burden without intervention over the cohort lifetime included 1,115,493 RSV hospitalizations, 929,841 RSV cases requiring emergency department (ED) care, and 10,633,808 RSV cases requiring a physician office (PO) visit; the corresponding total economic costs were MXN85.18 billion (US$4.24 billion). Assuming a 57.7% uptake, year-round RSVpreF vaccination would prevent 63,807 hospitalizations, 48,173 ED cases, and 317,435 PO cases. With 122,395 quality-adjusted life years (QALYs) gained, RSVpreF averts MXN7.12 billion (US$354.34 million) in direct medical costs. At an assumed willingness-to-pay threshold equivalent of 1xGDP per capita (MXN244,893.14 [US$13,790.02]) per QALY gained in Mexico, RSVpreF would be cost-effective up to MXN3,619.70 (US$199.30) per dose.
CONCLUSIONS: Year-round RSVpreF vaccination program would substantially reduce RSV’s clinical and economic burden among older adults in Mexico and likely be a highly cost-effective program.